Trial Profile
Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Alveolar soft part sarcoma; Chondrosarcoma; Chordoma; Clear cell sarcoma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Synovial sarcoma
- Focus Adverse reactions
- 01 Mar 2022 Final results from the dose escalation and expansion parts , published in the Radiotherapy and Oncology
- 25 Sep 2018 Status changed from active, no longer recruiting to completed.
- 25 Sep 2017 Planned End Date changed from 1 May 2017 to 1 Apr 2018.